NCT06383572View on ClinicalTrials.gov

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 26, 2024

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2029

Conditions
Lymphodepleting ChemotherapyMyeloid Malignancies
Interventions
DRUG

Cyclophosphamide

Given by IV

DRUG

Fludarabine phosphate

Given by IV

DRUG

Decitabine

Given by IV

DRUG

Dexamethasone

Given by mouth

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER